YL Biologics Reports the NDA Submission of YLB217 (biosimilar product of long-acting erythropoiesis stimulating agent Nesp)

 YL Biologics Reports the NDA Submission of YLB217 (biosimilar product of long-acting erythropoiesis stimulating agent Nesp)

YL Biologics Reports the NDA Submission of YLB217 (biosimilar product of long-acting erythropoiesis stimulating agent Nesp)

Shots:

  • YLB reported the NDA filing of YLB217, a biosimilar product of long-acting erythropoiesis-stimulating agent Nesp, which YLB solely developed, was executed through Yoshindo
  • On Sept 08, 2017, YLB signed a technology transfer agreement with CJ Healthcare, including exclusive development and marketing rights for Nesp biosimilar and started domestic development with the sponsorship of Yoshindo
  • In Jan’2019, YLB has conducted a P-III study that assesses YLB217 in 136 patients with renal anemia at 25 centers in Japan. Based on this, Yoshindo submitted a manufacturing and marketing approval application in Japan

Click here ­to­ read full press release/ article | Ref: YL Biologics | Image: YL Biologics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post